Prof. Stephen Johnston talks about the definition of Endocrine Therapy (ET) Resistance in HR+/HER2- MBC patients. He also discusses the effective role of abemaciclib + fulvestrant on overall survival in patients with primary and secondary resistance to ET.1,2 Reference 1. Cardoso F, Costa A, Senkus E, Aapro M, André F, et al. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Annals of Oncology.
2017 Dec 1;28(12):3111. 2. Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: a randomized clinical trial. JAMA oncology. 2020 Jan 1;6(1):116-24.